U-Ploid develops reproductive therapeutics designed to integrate into existing IVF procedures to improve outcomes. Their lead program targets improving egg quality in women over 35 by reducing meiotic aneuploidy, a primary cause of IVF failure. This science-driven approach aims to enhance the success rates of assisted reproductive technology for families.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related infertility presents a significant challenge for women seeking in vitro fertilization (IVF) treatment, as success rates decline with increasing maternal age due to diminished oocyte quality. Multiple IVF cycles are often required, increasing financial burden and emotional stress for patients.
Solution
U-Ploid Biotechnologies is developing therapeutics designed to enhance the quality of aged oocytes, thereby improving IVF success rates for women facing age-related infertility. Their approach focuses on integrating seamlessly with existing IVF protocols to improve egg quality. By improving the quality of older egg cells, U-Ploid aims to increase the likelihood of achieving healthy pregnancies in a single IVF cycle. This reduces the need for multiple cycles, making the process more accessible and sustainable.
Target Audience
The primary target audience includes women facing age-related infertility who are undergoing or considering IVF treatment, as well as fertility clinics seeking to improve their success rates with older patients.
Features
- Therapeutics designed to improve the quality of aged oocytes at a molecular level.
- Treatment protocols engineered for seamless integration with existing IVF workflows.
- Scalable solution suitable for global implementation in fertility clinics.